ID   Mero-48a
AC   CVCL_2593
SY   MERO48A
DR   cancercelllines; CVCL_2593
DR   Cell_Model_Passport; SIDM01867
DR   DepMap; ACH-001558
DR   ECACC; 09100104
DR   Wikidata; Q54905207
RX   PubMed=2474517;
RX   PubMed=25902174;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~24 hours (ECACC=09100104).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DepMap; ECACC
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 12
ST   D21S11: 27,32.2
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 13,14
ST   FGA: 19
ST   Penta D: 14
ST   Penta E: 16
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C45665; Pleural biphasic mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_W102 ! Mero-48b
OI   CVCL_W103 ! Mero-48c
OI   CVCL_W104 ! Mero-48d
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
//
RX   PubMed=2474517; DOI=10.1002/ijc.2910440212;
RA   Versnel M.A., Bouts M.J., Hoogsteden H.C., van der Kwast T.H.,
RA   Delahaye M., Hagemeijer A.;
RT   "Establishment of human malignant mesothelioma cell lines.";
RL   Int. J. Cancer 44:256-260(1989).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//